Climb Bio announces CLYM116 Phase 1 data in IgA nephropathy
Climb Bio says CLYM116 Phase 1 data shows prolonged half-life and APRIL suppression supporting every-12-week dosing in IgA nephropathy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.